Ad
related to: merck molecular bases of cancer- Lab Instrument Services
Qualified lab instrument engineers.
Experienced application scientists.
- About Us
Full-service medical lab consulting
Unparalleled reach and resources.
- Add a Testing Line
Already have a clinical lab?
Learn how we can add a testing line
- Contact Us
Ready to get started?
Get your free consultation today!
- Lab Instrument Services
Search results
Results from the WOW.Com Content Network
Molecular oncology is an interdisciplinary medical specialty at the interface of medicinal chemistry and oncology that refers to the investigation of the chemistry of cancer and tumors at the molecular scale. Also the development and application of molecularly targeted therapies.
Ifinatamab deruxtecan (DS-7300) is an experimental anti-cancer treatment developed by Merck and Daiichi Sankyo. It is an antibody–drug conjugate that "consists of an anti- B7-H3 antibody linked with a DNA topoisomerase I inhibiting anti-tumor agent".
Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer occurring in about three people per million members of the population. [1] It is also known as cutaneous APUDoma, primary neuroendocrine carcinoma of the skin, primary small cell carcinoma of the skin, and trabecular carcinoma of the skin. [2]
The treatment is one of three antibody-drug conjugates (ADCs) included in Merck's up to $22-billion joint development and commercialization deal with Daiichi Sankyo, signed last year.
Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from the HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in patients with locally advanced or metastatic EGFR-mutated non-small cell ...
Continuing its strategy of developing key partnerships with some of the pharma industry's biggest companies, Denmark-based Dako, Agilent Technologies' cancer diagnostics division, announced today ...
Cetuximab, sold under the brand name Erbitux, is an epidermal growth factor receptor (EGFR) inhibitor medication used for the treatment of metastatic colorectal cancer and head and neck cancer. [2] Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion .
Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.
Ad
related to: merck molecular bases of cancer